Brain Cancer
Biocept Licenses CNSide Liquid Biopsy Assay to Plus Therapeutics
Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium 186 obisbemeda.
Microenvironments Give Clues to Distinct Immunotherapy Responses in Brain Metastases, Glioblastomas
Investigators found microenvironment differences in checkpoint blockade immunotherapy-treated cases involving brain metastases versus recurrent glioblastoma.
New Mutations Identified in Common Childhood Brain Cancers Could Guide Personalized Treatments
In a study published in PNAS, Swedish researchers identified new mutations implicated in common pediatric cancers in the noncoding regions.
Biocept Prices $5M Public Offering
The San Diego-based company plans to use the proceeds to advance its cerebral spinal fluid liquid biopsy assay, as well as to boost its working capital.
The liquid biopsy assay uses low-pass whole-genome sequencing to screen for copy number alterations in blood, cerebral spinal fluid, and aqueous humor samples.